Fresenius Kabi Breaks Into Brazilian Biosimilars Market
Strikes State-Private Adalimumab Deal With Fiocruz/Bio-Manguinhos And Bionovis
• By Rosalind Rei
Fresenius’ Idacio will be the company’s first biosimilar on the Brazilian market • Source: Shutterstock 
